Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC

According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally advanced/metastatic solid tumor patients with KRAS G12C mutation. It involves patients with an ECOG PS of 0-1, measurable disease according to RECIST v1.1 standards. The main objectives are to determine the recommended phase II dose (RP2D) of LY3537982, its safety, pharmacokinetics (PK), and antitumor activity. Patients were divided into four dosage groups: 50 mg, 100 mg, 150 mg, and 200 mg taken twice daily. Dose expansion cohorts included combination treatments of LY3537982 with pembrolizumab (for NSCLC) and cetuximab (for CRC).
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies

The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year's AACR conference, three clinical trials were reported in the lymphoma field, including anti-CD19 immunotherapy Tafasitamab, CD19/CD20 CAR naive/memory T cells, and bispecific quadrivalent antibody (innate cell engager) AFM13.
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract

KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract

According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this approach demonstrated consistent survival benefits across geographical regions and PD-L1 expression subgroups. The KEYNOTE-966 study results were concurrently published in "The Lancet."
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo combined with chemotherapy.